Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TransMedics Group, Inc. (TMDX)
|
Add to portfolio |
|
|
|
| Price: |
$20.10
| | Metrics |
| OS: |
32.6
|
M
| |
-8
|
% ROE
|
| Market cap: |
$656
|
M
| |
-10
|
% ROIC
|
|
Net cash:
|
$136
|
M
| |
$4.18
|
per share
|
|
EV:
|
$519
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($10.8)
|
M
| |
|
|
| EPS |
($0.35)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-28-19 | Dec-29-18 | Dec-30-17 |
| Revenues | 162.0 | 93.5 | 81.7 | 30.3 | 59.7 | 25.8 | 14.7 | 7.7 |
| Revenue growth | 98.2% | 208.8% | 37.0% | | 130.8% | 76.3% | 90.7% | 23.8% |
| Cost of goods sold | 0.0 | 28.2 | 0.0 | 9.1 | 0.0 | 9.7 | 7.3 | 5.5 |
| Gross profit | 162.0 | 65.3 | 81.7 | 21.2 | 59.7 | 16.1 | 7.4 | 2.1 |
| Gross margin | 100.0% | 69.8% | 100.0% | 69.9% | 100.0% | 62.3% | 50.3% | 27.8% |
| Selling, general and administrative | 96.7 | 69.9 | 60.6 | 38.3 | 43.0 | 23.6 | 12.3 | 7.6 |
| Research and development | | | | | | 19.9 | 13.7 | |
| EBIT | -40.9 | -31.4 | -48.9 | -39.4 | -31.0 | -29.6 | -20.2 | -20.4 |
| EBIT margin | -25.2% | -33.6% | -59.9% | -130.3% | -52.0% | -114.5% | -138.1% | -265.8% |
| Pre-tax income | -36.2 | -36.2 | -44.2 | -44.2 | -28.7 | -33.5 | -23.7 | -20.8 |
| Income taxes | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | | | |
| Net income | -36.2 | -36.2 | -44.2 | -44.2 | -28.7 | -33.5 | -23.8 | -20.8 |
| Net margin | -22.4% | -38.8% | -54.1% | -146.1% | -48.2% | -129.8% | -162.1% | -271.0% |
| |
| Diluted EPS | ($1.23) | ($1.23) | ($1.60) | ($1.60) | ($1.16) | ($2.36) | ($17.48) | ($4.48) |
| Shares outstanding (diluted) | 29.6 | 29.6 | 27.6 | 27.6 | 24.7 | 14.2 | 1.4 | 4.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|